Live Breaking News & Updates on Interleukin 15 Superagonist
Stay updated with breaking news from Interleukin 15 superagonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
After several delays, the interleukin-15 superagonist Anktiva (nogapendekin alfa inbakicept) from Immunitybio Inc. has been approved by the U.S. FDA for treating bladder cancer, specifically Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ....